¼¼°èÀÇ ¿¢¼ÒÁ» ½ÃÀå(2024-2031³â)
Global Exosomes Market - 2024 - 2031
»óǰÄÚµå : 1560844
¸®¼­Ä¡»ç : DataM Intelligence
¹ßÇàÀÏ : 2024³â 09¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 186 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 4,350 £Ü 6,173,000
PDF & Excel (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 4,850 £Ü 6,882,000
PDF & Excel (Multiple User License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷Àå¿¡¼­ 7¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 7,850 £Ü 11,139,000
PDF & Excel (Enterprise License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.
¤± º¸°í¼­¿¡ µû¶ó ÃֽŠÁ¤º¸·Î ¾÷µ¥ÀÌÆ®ÇÏ¿© º¸³»µå¸³´Ï´Ù. ¹è¼Û±âÀÏÀº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

º¸°í¼­ °³¿ä

¼¼°è ¿¢¼ÒÁ» ½ÃÀåÀº 2023³â 13¾ï ´Þ·¯¿¡ ´ÞÇß°í, 2031³â¿¡´Â 27¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµÇ¸ç, 2024-2031³âÀÇ ¿¹Ãø ±â°£ µ¿¾È 15.6%ÀÇ ¿¬Æò±Õ º¹ÇÕ ¼ºÀå·ü(CAGR)À» ³ªÅ¸³¾ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¿¢¼ÒÁ»Àº Á¾¾ç±«»çÀÎÀÚ(TNF)¿¡ ÀÇÇØ À¯µµµÈ °£¿±Áٱ⼼Æ÷(TME)ÀÇ ½ÅÈ£Àü´ÞÀ» ¸Å°³Çϱâ À§ÇØ ¼¼Æ÷¿¡¼­ ºÐºñµÇ´Â 30-200nmÀÇ ¼ÒÆ÷·Î, ¼¼Æ÷¿¡¼­ ºÐºñµË´Ï´Ù. ¾Ï À¯¹ß EGFRÀº ¼¼Æ÷¿¡¼­ ¹èÃâµÇ¾î ´Ù¸¥ TME ¼¼Æ÷¿Í »óÈ£ ÀÛ¿ëÇÒ ¼ö ÀÖ½À´Ï´Ù. À§¾Ï ¼¼Æ÷ÀÇ ¿¢¼ÒÁ»Àº °£ ¹Ì¼¼ ȯ°æÀ» Á¶ÀýÇÏ°í °£ ÀüÀ̸¦ ÃËÁøÇÒ ¼ö ÀÖÀ¸¸ç, EGFRÀ» Æ÷ÇÔÇÏ´Â ¿¢¼ÒÁ»Àº ³»ÇÇ ¼¼Æ÷¿¡ Æ÷ȹµÇ¾î EGFR ÀÇÁ¸Àû ¹ÝÀÀ°ú VEGF ºÐºñ¸¦ À¯¹ßÇÒ ¼ö ÀÖÀ¸¸ç, EGFR µ¹¿¬º¯ÀÌ NSCLCÀÇ ¿¢¼ÒÁ»Àº CD8 T ¼¼Æ÷ÀÇ ¼¼Æ÷ »ç¸êÀ» ÃËÁøÇÒ ¼ö ÀÖ½À´Ï´Ù. ¸é¿ªÄ¡·áÀÇ È¿°ú¿¡ ¿µÇâÀ» ¹ÌÄ¥ ¼ö ÀÖ½À´Ï´Ù.

½ÃÀå ¿ªÇÐ :

ÃËÁø¿äÀΰú ¾ïÁ¦¿äÀÎ

¾Ï À¯º´·ü »ó½Â

¾Ï ¹ßº´·ü Áõ°¡·Î ÀÎÇØ Çõ½ÅÀûÀÎ Ä¡·á¹ý¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. Ç÷¾×, ¼Òº¯, Ÿ¾× µî ü¾× ³» ¹ÙÀÌ¿À¸¶Ä¿¸¦ ºÐ¼®Çϱâ À§ÇØ ¾×ü »ý°Ë°ú °°Àº ¿¢¼ÒÁ» ±â¹Ý ±â¼úÀÌ È°¿ëµÇ°í ÀÖ½À´Ï´Ù. ¿¢¼ÒÁ»Àº ºÐÀÚ Á¤º¸ÀÇ ¾ÈÁ¤ÀûÀÎ ¿î¹Ýü·Î¼­ ¾×ü »ý°Ë Á¢±Ù¹ý¿¡ ÀÌ»óÀûÀÎ Èĺ¸ÀÔ´Ï´Ù. ¿¬±¸ÀÚµéÀº ¿¢¼Ø ¹ÙÀÌ¿À¸¶Ä¿¸¦ Áúº´ ÁøÇà, Ä¡·á È¿°ú, ¹Ì¼¼ ÀÜÁ¸ º´º¯ÀÇ °ËÃâ¿¡ Ȱ¿ëÇÏ´Â ¹æ¾ÈÀ» ¸ð»öÇϰí ÀÖ½À´Ï´Ù.

¿¹¸¦ µé¾î, National Center for Health Statistics¿¡ µû¸£¸é 2023³â¿¡´Â ¹Ì±¹¿¡¼­ 195¸¸ 8,310¸íÀÇ ½Å±Ô ¾Ï ȯÀÚ°¡ ¹ß»ýÇϰí 60¸¸ 9,820¸íÀÇ ¾Ï »ç¸ÁÀÚ°¡ ¹ß»ýÇÒ °ÍÀ¸·Î ¿¹ÃøÇß½À´Ï´Ù. Àü¸³¼±¾Ï ¹ßº´·üÀº 20³â°£ °¨¼Ò¼¼¸¦ º¸ÀÌ´Ù°¡ 2014³âºÎÅÍ 2019³â±îÁö ¸Å³â 3%¾¿ Áõ°¡ÇÏ¿© 99,000¸íÀÇ ½Å±Ô ȯÀÚ°¡ Ãß°¡µÉ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ±×·¯³ª ±âŸ¿¡´Â ¿©¼º¿¡ ºñÇØ ³²¼ºÀÇ ¹ßº´ Ãß¼¼°¡ ´õ ¾çÈ£ÇÑ °ÍÀ¸·Î ³ªÅ¸³µ½À´Ï´Ù.

¿¢¼ÒÁ» ºÐ¸®ÀÇ ±â¼úÀû º¹À⼺°ú ±â¼úÀû ÇѰè

¿¢¼ØÀº Å©±â, ±¸¼º, ÀûÀç·®¿¡ µû¶ó Ư¡ÀÌ ´Þ¶óÁö±â ¶§¹®¿¡ °í¼øµµ ¹× ƯÀÌÀûÀ¸·Î ºÐ¸®ÇÏ´Â °ÍÀÌ ±â¼úÀû °úÁ¦ÀÔ´Ï´Ù. Ç¥ÁØÈ­µÈ ¹æ¹ýÀÌ ¾ø±â ¶§¹®¿¡ ½ÇÇè °á°úÀÇ ÆíÂ÷°¡ ¹ß»ýÇÏ¿© ¿¬±¸ °£ ºñ±³ °¡´É¼ºÀ» ¹æÇØÇÕ´Ï´Ù. ´Ù¸¥ ¼¼Æ÷¿Ü ¼ÒÆ÷¿Í ¿À¿°¹°ÁúÀÇ Á¸Àç·Î ÀÎÇØ ºÐ¸® °úÁ¤ÀÌ ±â¼úÀûÀ¸·Î ¾î·Æ½À´Ï´Ù. ¼ø¼öÇÏ°í ³ôÀº ¼öÀ²ÀÇ ¿¢¼ÒÁ» ºÐ¸®¸¦ ¼öÇàÇÏ·Á¸é °íµµÀÇ ±â¼úÀÌ ÇÊ¿äÇϸç, ÀÌ´Â ¾ò¾îÁø »ùÇÃÀÇ Ç°Áú°ú Àϰü¼º¿¡ ¿µÇâÀ» ¹ÌÄ¥ ¼ö ÀÖ½À´Ï´Ù.

½ÃÀå ¼¼ºÐÈ­

¼¼°è ¿¢¼ÒÁ» ½ÃÀåÀº Á¦Ç° À¯Çü, ¿ëµµ, ÃÖÁ¾ »ç¿ëÀÚ, Áö¿ªº°·Î ¼¼ºÐÈ­µË´Ï´Ù.

Á¦Ç° À¯Çüº°·Î´Â ŰƮ ¹× ½Ã¾àÀÌ ¿¢¼ÒÁ» ½ÃÀå Á¡À¯À²ÀÇ ¾à 47.3%¸¦ Â÷ÁöÇϰí ÀÖ½À´Ï´Ù.

Á¦Ç° À¯Çüº°·Î´Â ŰƮ ¹× ½Ã¾àÀÌ ¾à 47.3%¸¦ Â÷ÁöÇÕ´Ï´Ù. ŰƮ ¹× ½Ã¾àÀº ¿¢¼ÒÁ» ¿¬±¸ ¹× ÀÓ»ó Àû¿ë¿¡ ÇʼöÀûÀÎ µµ±¸ÀÔ´Ï´Ù. Ç÷¾×, ¼Òº¯, ¼¼Æ÷ ¹è¾ç¾×°ú °°Àº »ýü ½Ã·á¿¡¼­ ¿¢¼ÒÁ»À» ½±°Ô ºÐ¸®, °ËÃâ, ºÐ¼®ÇÒ ¼ö ÀÖµµ·Ï µ½½À´Ï´Ù. ÀÌ µµ±¸´Â »ý¹°ÇÐÀû ¹«°á¼ºÀ» À¯ÁöÇϸ鼭 ³ôÀº ¼öÀ²°ú ¼øµµ¸¦ º¸ÀåÇÕ´Ï´Ù. ÀÌ Å°Æ®´Â ºÐ¸® °úÁ¤À» ´Ü¼øÈ­ÇÏ¿© ±â¼úÀû Àü¹® Áö½ÄÀÌ ºÎÁ·ÇÑ »ç¶÷µéµµ »ç¿ëÇÒ ¼ö ÀÖµµ·Ï ÇÕ´Ï´Ù. Ç×ü ¹× ¿°·á¿Í °°Àº ½Ã¾àÀº ¿¢¼ÒÁ» Ç¥¸é ¸¶Ä¿¸¦ Ç¥ÁöÇÏ°í °ËÃâÇÏ¿© ¿¢¼ÒÁ» È­¹°À» Ư¼ºÈ­ÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ´Â Áø´Ü, ƯÈ÷ ¾Ï, ½Å°æ ÅðÇ༺ Áúȯ, ½ÉÇ÷°ü Áúȯ µîÀÇ ¹ÙÀÌ¿À¸¶Ä¿¸¦ ½Äº°ÇÏ´Â µ¥ ¸Å¿ì Áß¿äÇÕ´Ï´Ù.

¿¹¸¦ µé¾î, 2023³â 7¿ù ½Ã¸¶Áî(Shimadzu)°¡ °³¹ßÇÑ Exorapid-qIC´Â ´ÙÀÌ´ÏÈ¥µµÄÚ(Dainippon Book)°¡ Ãâ½ÃÇÑ ¼¼Æ÷¿Ü¼ÒÆ÷(CD9)¿ë ¸é¿ªÅ©·Î¸¶Åä±×·¡ÇÇ Å°Æ®·Î, ¼¼°è ÃÖÃÊ·Î ¿¢¼ÒÁ»À» Ç¥ÀûÀ¸·Î Çϴ ŰƮÀÔ´Ï´Ù. ÀÌ Å°Æ®¿¡´Â ±Ý ³ª³ë Ç÷¹ÀÌÆ® Ç¥Áö Ç×ü, ¸é¿ªÅ©·Î¸¶Åä±×·¡ÇÇ ½ÃÇèÁö, Çó±À¾× µîÀÌ Æ÷ÇԵǾî ÀÖ½À´Ï´Ù. ½Ã¸¶Áî´Â EVÀÇ À¯ÇüÀ» °ËÃâÇÏ°í °ËÃ⠽ýºÅÛÀ» ÃÖÀûÈ­ÇÏ´Â ¿ªÇÒÀ» ´ã´çÇϰí ÀÖ½À´Ï´Ù.

Áö¿ªº° ½ÃÀå ºÐ¼®

ºÏ¹Ì´Â ¿¹Ãø ±â°£ µ¿¾È Àüü ½ÃÀå Á¡À¯À²ÀÇ ¾à 38.4%¸¦ Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

ºÏ¹Ì´Â »õ·Î¿î ¹ÙÀÌ¿À¸¶Ä¿ °ËÃâÀ» À§ÇÑ Á¤ºÎ º¸Á¶±Ý Áõ°¡, ½ÉÇ÷°ü Áúȯ ¹× ¾Ï°ú °°Àº ¸¸¼º ÁúȯÀÇ ¹ß»ý·ü Áõ°¡·Î ÀÎÇØ ¿¹Ãø ±â°£ µ¿¾È Àüü ½ÃÀå¿¡¼­ ¾à 38.4%ÀÇ Á¡À¯À²À» Â÷ÁöÇÒ °ÍÀ¸·Î ÃßÁ¤/¿¹ÃøµË´Ï´Ù. ¶ÇÇÑ, ½Å¾à, Áø´Ü ¹× Ä¡·á¹ý °³¹ßÀ» À§ÇÑ ¿¬±¸°³¹ß Ȱµ¿ÀÌ È°¹ßÇØÁü¿¡ µû¶ó ÀÌ ºÐ¾ßÀÇ ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¿¹¸¦ µé¾î, 2024³â 7¿ù ½Å°æ ¿¢¼ÒÁ» ±â¹Ý ½Å°æ ÅðÇ༺ Áúȯ Ä¡·áÁ¦ÀÇ ¼±µÎÁÖÀÚÀÎ ¾Æ¸£³ª ¹ÙÀÌ¿À´Â ½Å°æ Áٱ⼼Æ÷ À¯·¡ ¿¢¼ÒÁ»ÀÎ ¸®µå ÇÁ·Î±×·¥ AB126¿¡ ´ëÇÑ ¹Ì±¹ ƯÇã 11,993,787È£¸¦ ÃëµæÇß½À´Ï´Ù. À̹ø ƯÇã´Â AB126ÀÇ ¹°Áú ±¸¼º°ú AB16À» ÀÌ¿ëÇÑ À¯ÀüÀÚ Ä¡·á¿ë Á¦Ç°¿¡ ´ëÇÑ º¸È£¸¦ È®´ëÇÏ´Â °ÍÀ¸·Î, 2038³â±îÁö ºÎ¿©µÉ ¿¹Á¤ÀÔ´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý°ú Á¶»ç ¹üÀ§

Á¦2Àå Á¤ÀÇ¿Í °³¿ä

Á¦3Àå ÁÖ¿ä ¿ä¾à

Á¦4Àå ½ÃÀå ¿ªÇÐ

Á¦5Àå »ê¾÷ ºÐ¼®

Á¦6Àå Á¦Ç° À¯Çüº°

Á¦7Àå ¿ëµµº°

Á¦8Àå ÃÖÁ¾»ç¿ëÀÚº°

Á¦9Àå Áö¿ªº°

Á¦10Àå °æÀï ±¸µµ

Á¦11Àå ±â¾÷ °³¿ä

Á¦12Àå ºÎ·Ï

LSH
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Report Overview

Global Exosomes Market reached US$ 1.3 billion in 2023 and is expected to reach US$ 2.7 billion by 2031, growing at a CAGR of 15.6% during the forecast period 2024-2031

Exosomes, small vesicles 30 to 200 nm, are secreted from cells to mediate signaling in the tumor necrosis factor (TNF)-induced mesenchymal stem cells (TME). Oncogenic EGFR can be shed from cells and interact with other TME cells. Exosomes from gastric cancer cells can regulate the liver microenvironment and promote liver metastasis. EGFR-containing exosomes can be captured by endothelial cells, eliciting EGFR-dependent responses and VEGF secretion. Exosomes from EGFR-mutated NSCLC can promote CD8+ T cell apoptosis, potentially affecting immunotherapy efficacy.

Market Dynamics: Drivers & Restraints

Rise in the prevalence of cancers.

The increasing prevalence of cancer has led to a growing demand for innovative therapies. Exosome-based technologies, such as liquid biopsy, are being used to analyze biomarkers in bodily fluids like blood, urine, or saliva. Exosomes, as stable carriers of molecular information, are ideal candidates for liquid biopsy approaches. Researchers are exploring the use of exosomal biomarkers for disease progression, treatment response, and detecting minimal residual disease.

For instance, according to the National Center for Health Statistics, In 2023, 1,958,310 new cancer cases and 609,820 cancer deaths are projected to occur in the United States. Cancer incidence increased for prostate cancer by 3% annually from 2014 through 2019 after two decades of decline, translating to an additional 99,000 new cases; otherwise, however, incidence trends were more favorable in men compared to women.

Technical complexity of exosome isolation and technological limitations

Exosomes, characterized by their size, composition, and cargo, present a technical challenge in isolating them with high purity and specificity. The absence of standardized methods can lead to variability in experimental outcomes and hinder comparability between studies. The isolation process is technically demanding due to the presence of other extracellular vesicles and contaminants. Obtaining pure and high-yield exosome isolation requires sophisticated techniques, which can affect the quality and consistency of the obtained samples.

Market Segment Analysis

The global exosomes market is segmented based on product type, application, end-user, and region.

The kits and reagents from the product type segment accounted for approximately 47.3% of the exosomes market share

The kits and reagents from the product type segment accounted for approximately 47.3%. Kits and reagents are essential tools in exosome research and clinical applications. They facilitate the isolation, detection, and analysis of exosomes from biological samples like blood, urine, and cell culture media. These tools ensure high yield and purity while preserving biological integrity. Kits simplify the isolating process, making it accessible to those with limited technical expertise. Reagents, like antibodies and dyes, label and detect exosomal surface markers, enabling the characterization of exosome cargo. This is crucial for diagnostics, particularly in identifying biomarkers for diseases like cancer, neurodegenerative disorders, and cardiovascular conditions.

For instance, in July 2023, Shimadzu Corporation developed Exorapid-qIC, an immunochromatography kit for extracellular vesicles (CD9) launched by Dai Nippon Toryo Co., Ltd., it is the world's first kit targeting exosomes. The kit includes gold nanoplate-labeled antibodies, immunochromatography test paper, and rinse solution. Shimadzu is responsible for detecting EV types and optimizing the detection system.

Market Geographical Analysis

North America is estimated to hold about 38.4% of the total market share throughout the forecast period

North America is estimated to hold about 38.4% of the total market share throughout the forecast period due to the rising government funding for the detection of new biomarkers and the increasing incidence of chronic conditions, such as cardiovascular diseases and cancer. In addition, growing research & development activities for the development of novel drugs, diagnostic methods, and treatment options are anticipated to drive the segment growth.

For instance, in July 2024, Aruna Bio, a leader in neural exosome-based therapeutics for neurodegenerative conditions, received a US Patent No. 11,993,787 for its lead program, AB126, an exosome derived from neural stem cells. The patent, which extends protection covering the composition of matter for AB126 and products for gene therapy using AB16, is expected to be granted by 2038.

Market Segmentation

By Product Type

Kits and Reagents

Instruments

Others

By Application

Cancer Applications

Lung Cancer

Breast Cancer

Prostate Cancer

Colorectal Cancer

Other

Non-Cancer Applications

By End User

Diagnostics

Hospitals & Clinical Testing Laboratories

Others

By Region

North America

U.S.

Canada

Mexico

Europe

Germany

UK

France

Italy

Spain

Rest of Europe

South America

Brazil

Argentina

Rest of South America

Asia-Pacific

China

India

Japan

South Korea

Rest of Asia-Pacific

Middle East and Africa

Market Competitive Landscape

The major global players in the market include STARTEK Health, Diagenode Inc., Fujifilm Holdings Corporation, Hitachi Chemical Diagnostics Inc., Lonza, MBL International, Miltenyi Biotec, Novus Biologicals, Qiagen, Thermo Fisher Scientific Inc. among others.

Key Developments

In January 2024, EXO Biologics SA, a Belgian biotech company committed to developing biopharmaceuticals using exosomes to treat rare diseases with high unmet medical needs, launched ExoXpert, a contract development and manufacturing organization (CDMO) specializing in exosomes. ExoXpert offers an MSC-based exosome manufacturing platform used in European clinical trials and is a wholly-owned subsidiary of EXO Biologics.

Why Purchase the Report?

To visualize the global exosomes market segmentation based on product type, application, end-user, and region as well as understand key commercial assets and players.

Identify commercial opportunities by analyzing trends and co-development.

Excel data sheet with numerous data points of the exosomes market level with all segments.

PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.

Product mapping available as excel consisting of key products of all the major players.

The global exosomes market report would provide approximately 64 tables, 61 figures, and 186 pages.

Target Audience 2024

Manufacturers/ Buyers

Industry Investors/Investment Bankers

Research Professionals

Emerging Companies

Table of Contents

1. Methodology and Scope

2. Definition and Overview

3. Executive Summary

4. Dynamics

5. Industry Analysis

6. By Product Type

7. By Application

8. By End User

9. By Region

10. Competitive Landscape

11. Company Profiles

12. Appendix

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â